NASDAQ:ACRX ACELRX PHARMACEUTICALS INC
After getting hammered in July from the FDA delaying approval on its' latest drug for pain relief, Bears have been piling on making an incredible 20% of the float short. Recent buy ratings from analysts could be the catalyst to get a short squeeze going to begin filling the gap left from the huge 40%+ drop in July. If momentum can carry the past 8, then 9 is a real possibility in a short amount of time. Two analysts have a hold rating while seven analysts have a buy rating including Jefferies Group that has a price target of $16.